NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp.’s (OTCBB: RBCC) potential acquisition of emerging Nano3D Biosciences (n3D) exemplifies the company’s new approach in biotechnology investment.
In an industry in which it typically takes many years, hundreds of millions of dollars and a little luck to produce a marketable product, RBCC is exploring a new model for success—seeking out later-stage bioscience companies with whom to partner.
“There are many great opportunities to look at in the biotech sector, but few meet our guidelines for participation,” said RBCC CEO Patrick Brown. “Nano3D Biosciences is a fully commercialized company with a complete and innovative new product that only lacks buyers. The relationship we’re pursuing with n3D is a prime opportunity for us to exhibit our skills and expertise in marketing and distributing technology breakthroughs to a global network.
“As we move to complete our deal with n3D, we’ll continue to look for similar opportunities,” he added.
For more information on Rainbow BioSciences, RBCC’s biotechnology division, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Elan Corp. (NYSE: ELN).
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.